Evidence map›Paper›PMID 28254410›Full record

ArticleCancer letters2017

Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.

Joseph P Burnett, Gi Lim, Yanyan Li, Ronak B Shah, Rebekah Lim, Hayley J Paholak, Sean P McDermott, Lichao Sun, Yasuhiro Tsume, Shuhua Bai and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 153 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Joseph P BurnettDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Gi LimSchool of Science and Humanities, Husson University, Bangor, ME 04401, USA.
Yanyan LiSchool of Science and Humanities, Husson University, Bangor, ME 04401, USA.
Ronak B ShahDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Rebekah LimDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, Husson University, Bangor, ME 04401, USA.
Hayley J PaholakDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Sean P McDermottDepartment of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Lichao SunDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Yasuhiro TsumeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.
Shuhua BaiDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, Husson University, Bangor, ME 04401, USA.
Max S WichaDepartment of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Duxin SunDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: duxins@med.umich.edu.
Tao ZhangDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, Husson University, Bangor, ME 04401, USA. Electronic address: zhangt@husson.edu.
University of Michigan–Ann Arbor · USHusson University · US

Funding

Targeting breast cancer stem cellsR35CA197585 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WICHA, MAX S. · 2016 to 2022
$6.4M
NCI NIH HHS R35 CA197585
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) typically exhibits rapid progression, high mortality and faster relapse rates relative to other breast cancer subtypes. In this report we examine the combination of taxanes (paclitaxel or docetaxel) with a breast cancer stem cell (CSC)-targeting agent sulforaphane for use against TNBC. We demonstrate that paclitaxel or docetaxel treatment induces IL-6 secretion and results in expansion of CSCs in TNBC cell lines. Conversely, sulforaphane is capable of preferentially eliminating CSCs, by inhibiting NF-κB p65 subunit translocation, downregulating p52 and consequent downstream transcriptional activity. Sulforaphane also reverses taxane-induced aldehyde dehydrogenase-positive (ALDH+) cell enrichment, and dramatically reduces the size and number of primary and secondary mammospheres formed. In vivo in an advanced treatment orthotopic mouse xenograft model together with extreme limiting dilution analysis (ELDA), the combination of docetaxel and sulforaphane exhibits a greater reduction in primary tumor volume and significantly reduces secondary tumor formation relative to either treatment alone. These results suggest that treatment of TNBCs with cytotoxic chemotherapy would be greatly benefited by the addition of sulforaphane to prevent expansion of and eliminate breast CSCs.

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCell DeathCell Line, TumorCell ProliferationDocetaxelDose-Response Relationship, DrugFemaleGene Expression Regulation, NeoplasticHumansInflammation MediatorsInterleukin-6Interleukin-8IsothiocyanatesMice, Inbred NODMice, SCIDCXCL8 protein, humanDocetaxelIL6 protein, humanInflammation MediatorsInterleukin-6Interleukin-8IsothiocyanatesNF-kappa B p52 SubunitNFKB2 protein, humanPaclitaxelRELA protein, humansulforaphaneSulfoxidesTaxoidsTranscription Factor RelATubulin ModulatorsCancer stem cellDocetaxelPaclitaxelSulforaphaneTriple negative breast cancer

Identifiers

PMID28254410
PMCPMC8892390
OpenAlexW2593864463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.